ArticleScientific reports2025
Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discordance between Breast and Axillary Responses After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Implications for Surgical De-Escalation.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is reported that HER2-low breast cancer (BC) demonstrates a poor response to neoadjuvant chemotherapy (NACT), whereas the response and impact of HER2-low triple-negative breast cancer (TNBC) to NACT remain controversial. TNBC patients who received standard NACT at Tianjin Medical University Cancer Hospital were retrospectively enrolled. The pathological complete response (pCR) rate of NACT were compared between HER2-low and HER2-zero patients. Logistic regression analyses were performed to identify the independent factors affecting the pCR rate in patients with HER2-low TNBC after NACT. We finally included 369 HER2-low and 245 HER2-zero patients with TNBC. The axillary lymph nodes pathological complete response (npCR) rate and total pathological complete response (tpCR) rate after NACT in the HER2-low group were worse than that in the HER2-zero group, and there was no statistical difference in breast pathological complete response (bpCR) between the two groups. In HER2-low TNBC patients, multivariate analysis showed that early clinical lymph node stage, high Ki67 expression, use of immunotherapy and bpCR were independent influencing factors for npCR. Premenopause, small clinical tumor size, early clinical lymph node stage, CK5/6 positivity and EGFR negativity were independent factors affecting tpCR. The npCR and tpCR of HER2-low TNBC patients are worse than those of HER2-zero TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.